Curr Opin Immunol. 2025 Oct 30;98:102685. doi: 10.1016/j.coi.2025.102685. Online ahead of print.

ABSTRACT

Regulatory T cells (Tregs) are a rare subset of T cells that are potent regulators of the immune system. As a result, the use of Tregs to prevent undesired immune activation and to re-establish immune balance is an attractive cellular therapy approach. In hematopoietic cell transplantation (HCT), there has been significant interest in using Tregs to prevent graft-versus-host disease (GVHD), which occurs when donor alloreactive T cells recognize recipient HLA- or other minor transplantation antigens as non-self. There is a critical unmet need for novel strategies to prevent GVHD since as many as 50% of patients will develop clinically significant GVHD with current therapies. Evidence from preclinical murine models and early-phase human studies suggests that an additional benefit to Treg cellular therapy in HCT is the apparent maintenance of pathogenic immunity and graft-versus-tumor effects, which are required to prevent leukemia relapse. While the major limiting factor for Treg-based therapies has been the rarity of these cells, novel methods to improve Treg isolation and expansion have demonstrated feasibility for implementation of these strategies in the clinic. Moreover, genetic engineering of Tregs has been shown to be a promising strategy to improve their specificity, longevity, and function. Clinical trials have established that such approaches are feasible and can be effective in both human leukocyte antigen (HLA)-matched and haplo-matched settings. In this review, we describe proposed mechanisms for Treg control of alloreactivity, modern methods for Treg isolation and expansion, the history of Treg clinical trials for GVHD prevention, and the horizon for Treg cellular therapy.

PMID:41172558 | DOI:10.1016/j.coi.2025.102685